Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

REGENT PACIFIC GROUP LIMITED
勵晶太平洋集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 575)

Voluntary Announcement
Revised Launch Timetable of Accrua Health™ – Deep Longevity's Consumer Digital Health Platform in the United States

This announcement is made by the board (the "**Board**") of directors (the "**Director(s)**") of Regent Pacific Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company (the "**Shareholders**") and potential investors informed of the latest business developments of the Group.

Update on Launch of Accrua Health™ by Deep Longevity

Reference is made to the announcement of the Company dated 28 September 2026 (the "**Announcement**"). Capitalised terms herein shall have the same meanings as defined in the Announcement.

The Board is pleased to provide an update on the preparations for the Launch of Accrua Health™ (renamed from Accrua™ to Accrua Health™, "**Accrua Health**"), Deep Longevity's consumer digital health and telehealth platform in the US. The Launch is now expected to take place in Q4 2026 with an invite-only soft launch during Q4 2026, followed by a public waitlist phase and a full scale commercial launch. This short extension reflects the onboarding of Deep Longevity's telehealth infrastructure partners and digital advertising agency, and the time taken to ensure the seamless integration of Deep Longevity's BloodAge report into the electronic health record (EHR) platform of one of those partners. The Board believes this investment will provide a strong operational foundation for a successful Launch.

Accrua Health will be introduced in phases, enabling Deep Longevity to begin marketing and building patient volume sooner while establishing a strong operational base before expanding its offering. Phase 1 will comprise medical weight loss, longevity and anti-aging peptides; Phase 2 will add testosterone and hormone replacement therapies; and Phase 3 will introduce further programmes guided by patient demographics, demand and evolving business priorities. Deep Longevity is also working towards compliance with the Health Insurance Portability and Accountability Act (HIPAA) to coincide with the Launch, as part of its strategy to deepen its presence in the US healthcare ecosystem.

The Launch represents the culmination of Deep Longevity's strategy, as set out in the Company's 2026 interim results announcement and 2026 interim report dated 25 August 2026, of scaling in the US market through a D2C digital telehealth offering. The Board regards Accrua Health as a potentially transformational development for the Group and a significant new source of future revenue, complementing Deep Longevity's existing B2B model.

About Accrua Health

Accrua Health provides simple, direct online medical care led by licensed US clinicians. At its heart is Deep Longevity's proprietary, AI-generated BloodAge report, which uses a routine blood test to indicate whether a consumer is a "faster ager" – someone whose biological age is advancing more quickly than their chronological age.

Following a clinician consultation, Accrua Health offers doctor-guided access to treatment categories including weight loss (such as GLP-1 therapies), peptides and, in later phases, men's health (such as testosterone therapies) and women's health (such as hormone replacement therapy). Each treatment plan is personalised by a licensed clinician and anchored to the user's BloodAge report, which is re-measured quarterly so that users and clinicians can track the effect of treatment against an objective, science-based measure of biological ageing.

Accrua Health is built around a simple proposition – "You know your age. Your blood knows better." – combining quarterly biological age measurement, clinician-guided protocols and compounded therapies in an integrated longevity care programme, backed by peer-reviewed science.

Accrua Health extends access to Deep Longevity's deep learning ageing clock technology and SenoClock® platform directly to consumers for the first time, alongside Deep Longevity's existing work with clinics, hospitals, laboratories and insurance companies.

Cautionary Statement

Shareholders and potential investors should note that Accrua Health is a new business and that the revenues to be generated from it, if any, are uncertain and will depend on a number of factors, including consumer demand, customer acquisition costs, competition, the performance of third party clinical and fulfilment partners, and the regulatory environment for digital telehealth and compounded medications in the US. The timetable and phasing described above are indicative and remain subject to change. The commercialisation progress and market benefits of Accrua Health remain uncertain and may not generate anticipated returns for the Group, and this announcement does not constitute a forecast of Accrua Health's performance. As at the date of this announcement, the aforementioned development is not expected to have any material impact on the Group's financial position or operating results for the financial year ending 31 December 2026. The Company will issue separate announcement(s) as and when appropriate regarding any material progress in the aforementioned development, in accordance with the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the shares of the Company.

By Order of the Board
Regent Pacific Group Limited
Jamie Gibson
Executive Director

Hong Kong, 30 October 2026

As at the date of this announcement, the Board comprises six Directors**:**

Executive Director:
Jamie Gibson *(Chief Executive Officer)*

Non-Executive Directors:
James Mellon *(Chairman)*
Jayne Sutcliffe

Independent Non-Executive Directors:
Mark Searle
Adrian Chan
Ihsan Al Chalabi